CoChat

Marine-Based Omega-3 Fatty Acids and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 6 of the 10 sources its claims cite were checked for support.

Abstract

BACKGROUND: -3 PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may improve MetS components through triglyceride-lowering, anti-inflammatory, and insulin-sensitizing effects; however, randomized controlled trial (RCT) results remain inconsistent, and the influence of dose and intervention duration is unclear. METHODS: Following PRISMA guidelines, PubMed, Embase, Scopus, and Web of Science were searched to June 2024 for RCTs in adults with MetS or its components. Eligible trials assessed marine-derived omega-3 supplementation (EPA/DHA) versus placebo or control and reported at least one MetS diagnostic criterion (triglycerides, HDL cholesterol, fasting plasma glucose, blood pressure, or waist circumference) or related parameter (LDL cholesterol, HOMA-IR, or HbA1c). Data were extracted in duplicate and quality assessed using the Cochrane Risk-of-Bias Tool. Trials were categorized by dose-low (<1000 mg/day), medium (1000-2000 mg/day), and high (>2000 mg/day)-and duration: short-term (ST; ≤8 weeks), medium-term (MT; >8-12 weeks), and long-term (LT; >12 weeks). Meta-regression using ordinary least squares estimated dose-duration effects. Publication bias was assessed with funnel plots and Egger's test for outcomes with ≥3 studies. RESULTS: < 0.001) was observed. In other subgroups, either there were no data available or the number of studies was limited and could not be considered as statistically significant in meta-analysis due to low power. As for HDL cholesterol, FBS, SBP, DBP, waist circumference, BMI, and HOMA-IR, the data extracted from the included studies were not sufficient to be eligible for the meta-analysis. CONCLUSIONS: Marine-derived omega-3 supplementation produces substantial triglyceride reductions, especially at doses >2000 mg/day for ≥8 weeks. HDL cholesterol and blood pressure benefits are not consistent, fasting glycemia is largely unaffected, and LDL cholesterol may increase, especially in low doses. High-dose marine omega-3s can be considered as part of dietary strategies for MetS management, with monitoring for LDL changes. Standardized intervention protocols and long-term RCTs are needed to clarify dose and duration-response relationships.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 21 RCTs (n ≈ 1950) found that marine-derived omega-3 supplementation substantially lowers triglycerides, especially at high doses (>2000 mg/day), but effects on HDL cholesterol, fasting glucose, and blood pressure were inconsistent or limited. Low-dose omega-3 was associated with increased LDL cholesterol, and some evidence suggested possible worsening of insulin resistance at low long-term doses.

Key findings

  • Triglycerides: pooled analysis across 17 studies showed a significant reduction (SMD −0.53; 95% CI −0.69 to −0.37; p < 0.001; I² = 26%). High-dose reductions were −50.87 mg/dL for short-term, −41.54 mg/dL for medium-term, and −56.78 mg/dL for long-term (all p < 0.001); medium-dose reductions were −24.93 mg/dL for medium-term and −31.84 mg/dL for long-term (all p < 0.001). Low-dose protocols showed no significant TG effects.
  • LDL cholesterol: significant increases occurred in low-dose short-term (+7.04 mg/dL; p < 0.001) and low-dose long-term (+35.53 mg/dL; p < 0.001) groups, confirmed in meta-regression. A high-dose long-term increase (+10.28 mg/dL; p < 0.001) was based on only two studies and not eligible for meta-regression.
  • Fasting blood glucose: pooled effect across 11 studies was non-significant (SMD −0.10; 95% CI −0.29 to +0.08; p = 0.271; I² = 52%). HDL cholesterol, blood pressure, waist circumference, BMI, and HbA1c had insufficient data for robust meta-analysis; isolated HDL and blood pressure findings were low-power.
  • HOMA-IR: high-dose medium-term showed a reduction (−1.337; p < 0.001) and high-dose long-term a smaller reduction (−0.25; p < 0.001), both from only two studies. Low-dose long-term showed an increase (+0.940; p < 0.001), also based on two studies and not confirmed in meta-regression.

Methods

  • PRISMA-guided systematic review and meta-analysis; PubMed, Embase, Scopus, and Web of Science searched from 2000 to June 2024. From 187 records, 21 RCTs in adults with metabolic syndrome or its components met inclusion criteria; eligible trials compared marine-derived EPA/DHA supplementation with placebo or control and reported at least one MetS diagnostic criterion or related parameter.
  • Trials were categorized by dose—low (<1000 mg/day), medium (1000–2000 mg/day), high (>2000 mg/day)—and duration—short-term (≤8 weeks), medium-term (>8–12 weeks), long-term (>12 weeks). Ordinary least squares meta-regression estimated dose–duration effects using a simulated weighted dataset derived from aggregated study results.
  • Quality was assessed with the Cochrane Risk-of-Bias Tool version 2. Publication bias was assessed with funnel plots and Egger’s test for outcomes with at least three studies.

Limitations

  • The paper states that some subgroup results came from only one or two studies, limiting generalizability and preventing inclusion in meta-regression; variations in EPA-to-DHA ratios, baseline metabolic status, and co-interventions such as diet or exercise may have contributed to heterogeneity.
  • The paper states that most trials did not report diet or physical activity in sufficient detail, so lifestyle changes could not be adjusted for and may confound results; none of the included studies assessed LDL particle characteristics, making LDL-C increases harder to interpret.
  • Evident from the text: the analysis simulated a weighted dataset from aggregated results rather than using individual participant data, and many outcomes (HDL-C, FBS, blood pressure, waist circumference, BMI, HbA1c) had insufficient data or low statistical power. Publication bias could not be assessed for outcomes with fewer than three studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu17203279

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Prisma flowchart.
Figure 1 Prisma flowchart.CC BY · PubMed Central
Figure 2 Risk-of-bias assessment for included articles [2,3,6,7,8,9,10,11,13,14,15,16,17,18,19,20,21,22,23,24,25]. Green: Low Risk, Yellow: Unclear risk, Red: High Risk.
Figure 2 Risk-of-bias assessment for included articles [2,3,6,7,8,9,10,11,13,14,15,16,17,18,19,20,21,22,23,24,25]. Green: Low Risk, Yellow: Unclear risk, Red: High Risk.CC BY · PubMed Central
Figure 3 Risk assessment for bias (percentage).
Figure 3 Risk assessment for bias (percentage).CC BY · PubMed Central
Figure 4 Forest plots of the effect of marine omega-3 supplementation on metabolic syndrome (MetS) parameters and other MetS-related biochemical markers. Each trial is shown with study name, effect size (MD in native units or SMD where required), and 95% CI; square size reflects inverse-variance weight. The red dotted line indicates Zero. Abbreviations: SBP: systolic blood pressure. DBP: diastolic blood pressure. FBS: fasting blood sugar [2,3,6,7,8,9,10,11,13,14,15,16,17,18,19,20,21,22,23,24,25].
Figure 4 Forest plots of the effect of marine omega-3 supplementation on metabolic syndrome (MetS) parameters and other MetS-related biochemical markers. Each trial is shown with study name, effect size (MD in native units or SMD where required), and 95% CI; square size reflects inverse-variance weight. The red dotted line indicates Zero. Abbreviations: SBP: systolic blood pressure. DBP: diastolic blood pressure. FBS: fasting blood sugar [2,3,6,7,8,9,10,11,13,14,15,16,17,18,19,20,21,22,23,24,25].CC BY · PubMed Central

Verification

Claims the paper makes

3 Valid · 4 Not valid · 4 Not checked · 84 Own results and interpretations

33 more claims

Create a free account to see all 95 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 51

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Cited by

See all 9

Metadata

Authors
Basirat, A., & Merino-Torres, J. F.
Affiliations
  • Instituto de Investigación Sanitaria La Fe (ES)
  • Universitat de València (ES)
Corresponding author
  • Basirat, Arghavan
  • Merino-Torres, Juan Francisco
Venue
Nutrients
Publisher
MDPI AG
Published
2025-10-18
Volume
17
Issue
20
Pages
3279
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4415361258
Cited by
9
References
29
Citations by year
2026: 9
FWCI
1.19
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
Keywords
omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, metabolic syndrome, triglyceride lowering, HDL cholesterol, LDL cholesterol, fasting blood glucose, blood pressure, waist circumference, insulin resistance, dose-duration relationship
MeSH terms
Adult, Blood Glucose, Docosahexaenoic Acids, Female, Humans, Male, Middle Aged, Triglycerides, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Randomized Controlled Trials as Topic, Dietary Supplements, Metabolic Syndrome, Aquatic Organisms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.